ADC Therapeutics SA (ADCT)
4.125
+0.04
(+0.86%)
USD |
NYSE |
May 17, 16:00
4.125
0.00 (0.00%)
After-Hours: 20:00
ADC Therapeutics Research and Development Expense (Quarterly): 25.74M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 25.74M |
| December 31, 2023 | 27.26M |
| September 30, 2023 | 28.44M |
| June 30, 2023 | 31.94M |
| March 31, 2023 | 38.38M |
| December 31, 2022 | 47.29M |
| September 30, 2022 | 41.68M |
| June 30, 2022 | 48.54M |
| March 31, 2022 | 48.95M |
| December 31, 2021 | 42.49M |
| Date | Value |
|---|---|
| September 30, 2021 | 36.80M |
| June 30, 2021 | 39.53M |
| March 31, 2021 | 39.17M |
| December 31, 2020 | 48.55M |
| September 30, 2020 | 32.16M |
| June 30, 2020 | 25.95M |
| March 31, 2020 | 35.38M |
| December 31, 2019 | 30.42M |
| September 30, 2019 | 30.54M |
| June 30, 2019 | 21.76M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
21.76M
Minimum
Jun 2019
48.95M
Maximum
Mar 2022
36.05M
Average
36.09M
Median
Research and Development Expense (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Novartis AG | 2.421B |
| AC Immune SA | 17.35M |
| CRISPR Therapeutics AG | 76.17M |
| Addex Therapeutics Ltd | 0.5126M |